Antibe Therapeutics Inc
🇨🇦Canada
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 11
- Market Cap
- -
- Introduction
Antibe Therapeutics Inc is leveraging its proprietary hydrogen sulfide platform to develop next-generation safer therapies to target inflammation arising from a wide range of medical conditions. The company's pipeline includes assets that seek to overcome gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs. Antibe's lead drug, otenaproxesul, is in clinical development as a safer alternative to opioids for post-operative pain. Antibe's second pipeline drug, ATB-352, is being developed for a specialized acute pain indication. The company's anticipated next target is inflammatory bowel disease, a condition long in need of safer, more effective therapies.
ROSALINE Trial: Neoadjuvant Letrozole/Entrectinib Shows Limited Efficacy in Invasive Lobular Breast Cancer
• The phase 2 ROSALINE trial found that combining entrectinib with letrozole failed to meet its primary endpoint, with no efficacy-evaluable patients achieving residual cancer burden (RCB) of 0 or 1 in invasive lobular breast cancer.
• Despite the primary endpoint failure, the treatment showed a 49% objective response rate by MRI assessment, with 10% complete responses and 39% partial responses among the 41 evaluable patients.
• ROSALINE represents the first neoadjuvant endocrine therapy trial dedicated exclusively to invasive lobular breast cancer, demonstrating the feasibility of subtype-specific trials while researchers continue biomarker analyses.
Invivyd Challenges FDA with Citizen Petition to Prioritize Monoclonal Antibodies for COVID-19 Prevention
• Invivyd has submitted a Citizen Petition urging the FDA to reevaluate COVID-19 prevention strategies, emphasizing the need for monoclonal antibodies alongside vaccines in the endemic phase of the virus.
• The company argues that current vaccine efficacy data is outdated, as it was collected when Americans were immunologically naïve and before immune-evasive Omicron variants emerged.
• Invivyd recommends new clinical trials for COVID-19 vaccines that include seropositive patients, test against contemporary variants, and measure efficacy over at least six months.
Pfizer to Showcase Breakthrough Cancer Therapies at ASCO 2025 with Over 60 Presentations
• Pfizer will present data from more than 60 abstracts at ASCO 2025, including 15 oral presentations highlighting advancements across breast, genitourinary, hematologic, thoracic, and colorectal cancers.
• Two late-breaking presentations will be featured in ASCO's press program, including pivotal survival data for BRAFTOVI in colorectal cancer and progression-free survival results for vepdegestrant in metastatic breast cancer.
• The company will showcase novel antibody-drug conjugate combinations with immunotherapy and present five-year survival data for XTANDI in prostate cancer, supporting Pfizer's goal of delivering eight breakthrough cancer medicines by 2030.
Awakn's AWKN-002 Receives FDA Support for Phase 2b Trial in Alcohol Use Disorder
• Awakn Life Sciences received FDA support to advance AWKN-002, an oral thin film esketamine, to a Phase 2b trial for moderate to severe Alcohol Use Disorder (AUD).
• The FDA confirmed that no additional clinical data is required before initiating the Phase 2b trial, streamlining the development pathway for AWKN-002.
• AWKN-002 is eligible for review under the 505(b)(2) NDA pathway, potentially granting up to 5 years of market exclusivity in the U.S. for AUD treatment.
• Awakn plans to submit an IND application for AWKN-002 in H2 2025, followed by a Phase 2b trial application in H1 2026, aiming to address the unmet needs in AUD treatment.
CytoMed and SunAct Partner to Advance Gamma Delta T-Cell Therapy for Solid Tumors in India
• CytoMed Therapeutics and SunAct Cancer Institute collaborate to evaluate allogeneic gamma delta T cells for solid tumor treatment in a Phase 2 trial.
• The trial will assess the safety, tolerability, potency, and efficacy of CytoMed's cell therapy across various solid cancer types.
• CytoMed will provide technical support and manufacture the cell therapy, while SunAct will offer local expertise and access to patients in India.
• This collaboration aims to provide an affordable cancer treatment option and contribute to the global data pool for cancer research.
Three Major Trends Reshaping Precision Medicine: AI, CRISPR, and mRNA Technologies Lead Innovation
• Precision medicine deals reached $97.39 million in 2023, with cell therapies projected to generate over $52 billion by 2029, marking significant growth in personalized treatment approaches.
• AI is revolutionizing precision medicine by accelerating genomic data analysis, drug discovery, and enabling personalized treatment predictions through platforms like Tempus and Foundation Medicine.
• CRISPR gene editing achieved a milestone with FDA approval of Casgevy for sickle cell disease, while mRNA technology expands beyond COVID-19 with Moderna's mRESVIA approval for RSV.
© Copyright 2025. All Rights Reserved by MedPath